×

Cramer Examines BioMarin Pharmaceuticals

6:15 PM ET Tue, 19 June 2012

Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses his company's efforts to develop treatment products for Lysosomal Storage Disorders. "We are the opposite of big pharma, we look at a significant improvement in a small patient population," says Bienaime.